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Association of Atypical Femoral Fractures
with Bisphosphonate Use by Patients with
Varus Hip Geometry
Jennifer E. Hagen, MD, Anna N. Miller, MD, Susan M. Ott, MD, Michael Gardner, MD, Saam Morshed, MD, Kyle Jeray, MD,
Timothy B. Alton, MD, Dennis Ren, BS, W. Parker Abblitt, MD, and James C. Krieg, MD
Background: There is increasing evidence associating “atypical” femoral fractures with prolonged exposure to bis-
phosphonate therapy. The cause of these fractures is unknown and likely multifactorial. This study evaluated the hy-
pothesis that patients with primary osteoporosis who sustain atypical femoral fracture(s) while on chronic bisphosphonate
therapy have a more varus proximal femoral geometry than patients who use bisphosphonates for primary osteoporosis
but do not sustain a femoral fracture.
Methods: The femoral neck-shaft angle was measured on the radiographs of 111 patients with atypical femoral shaft
fracture(s) and thirty-three asymptomatic patients; both groups were on chronic bisphosphonate therapy. Patients with
characteristic lateral cortical thickening, stress lines, and thigh pain were included in the fracture group.
Results: The mean neck-shaft angle of the patients who sustained atypical femoral fracture(s) while taking bisphos-
phonates (case group) differed signiﬁcantly from that of the patients on bisphosphonate therapy without a fracture
(129.5 versus 133.8; p < 0.001). Fifty-three (48%) of the patients in the case group had a neck-shaft angle that was
lower than the lowest angle in the control group (128). Side-to-side comparison in patients with a unilateral pathologic
involvement and an asymptomatic contralateral lower limb did not demonstrate any signiﬁcant difference between the
neck-shaft angles in the two limbs.
Conclusions: Patients on chronic bisphosphonate therapy who presented with atypical femoral fracture(s) had more
varus proximal femoral geometry than those who took bisphosphonates without sustaining a fracture. Although no
causative effect can be determined, a ﬁnding of varus geometry may help to better identify patients at risk for fracture after
long-term bisphosphonate use.
Level of Evidence: Prognostic Level III. See Instructions for Authors for a complete description of levels of evidence.
A
n estimated 10 million Americans have osteoporosis,
and more than 1.5 million fractures per year are attrib-
uted to this disease1. Since their introduction in 1995,
bisphosphonates have become the standard of care for treatment
of osteoporosis, and more than 4 million women in the United
States were taking bisphosphonates in 20082. In 2005, reports
began to appear of “atypical” femoral fractures in patients on
bisphosphonate therapy for a prolonged period of time. Many
studies have evaluated the association between the use of bis-
phosphonates and the occurrence of an atypical fracture3-7, and
a recent meta-analysis suggested an increased risk for atypical
femoral fractures in patients taking a bisphosphonate3. In a
study of 716 femoral shaft fractures in patients on bisphosphonate
therapy, Park-Wyllie et al. found that patients on bisphosphonate
therapy for longer than ﬁve years had a 2.74 times increased risk of
diaphyseal femoral fracture as compared with a control group4.
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Schilcher et al. found the odds ratio of atypical fracture in
patients on bisphosphonate therapy to be 33.3 after adjusting
for comorbid conditions8. The risk increased with prolonged
use and was ten times higher than normal after just two years8.
We believe that other risk factors must also be present to
explain why (1) only a small percentage (0.02% to 0.2%) of
patients taking bisphosphonates on a chronic basis develop
these fractures and (2) atypical femoral fractures sometimes
occur in patients who are not on long-term therapy5. It is possible
that patients who develop atypical femoral fractures have an
anatomic biomechanical predisposition. We hypothesized that
patients on chronic bisphosphonate therapy who sustain
atypical femoral fracture(s) or display radiographic character-
istics consistent with a stress fracture or “lateral cortical beaking”7
are more likely to have varus proximal femoral anatomy than
exposure-matched controls.
Materials and Methods
We performed a multicenter retrospective case-control study of patientsfrom six institutions. Institutional review board approval was obtained
at each individual site. A series of 111 patients who had been treated for a
complete or incomplete atypical femoral fracture were identiﬁed. Each patient
had radiographic characteristics of the atypical femoral fracture associated with
chronic bisphosphonate use. To be included in the study group, those without a
complete fracture had to have thigh or hip pain in addition to radiographic
evidence of either lateral cortical beaking or a transverse stress line based on
ASBMR (American Society for Bone andMineral Research) criteria
6
. These 111
patients constituted the case group. All radiographs were reviewed and ap-
proved for inclusion by senior authors (J.C.K., A.N.M., S.M.O, S.M., K.J., and
M.G.) at each institution. Exclusion criteria included bisphosphonate therapy
for diseases other than primary osteoporosis, previous hip arthroplasty, and
radiographs not being available.
A control group of thirty-three patients was identiﬁed. These patients
had a documented duration of bisphosphonate use for primary osteoporosis;
no history of fracture; no history of prodromal thigh or hip pain; and hip,
pelvic, or femoral radiographs already in the medical record (Table I).
One hundred and forty-four patients were included in the analysis, and
radiographs of 255 hips were available formeasurement. All patients are female.
The radiographs were compiled and reviewed at three sites where the senior
authors (J.C.K., A.N.M., and M.G.) practiced. One reviewer was a trauma
trained attending surgeon. The other two were a senior resident and a medical
student, who could consult with trauma trained attending surgeons for guid-
ance. The reviewers were aware of the hypothesis of the study. A sample of
radiographs was sent to all four reviewers, and the interobserver difference
between the neck-shaft angle measurements was <1 (standard deviation [SD],
1.6). Intraobserver reliability was not calculated.
Measurements were made on anteroposterior radiographs of both hips,
when radiographs of both were available. The neck-shaft angle was deﬁned as
the angle formed by the intersection of a line down the center of the femoral
neck and a line through the center of the femoral shaft
9
. We did not arbitrarily
assign a cutoff neck-shaft angle to deﬁne varus geometry; rather, it was recorded
as a continuous variable. Measurements of each hip were recorded as inde-
pendent data, and measurements in the case group were divided into those
on the “pathologic” side(s) and those on the asymptomatic side. The mea-
surements from the pathologic side(s) were compared with the control group
as well as the asymptomatic sides of the patients with a unilateral pathologic
involvement. The asymptomatic sides of these patients were measured to de-
termine if there was a side-to-side variation in anatomy that correlated with
unilateral pathologic involvement.
For patients for whom only post-fracture radiographs were available,
the center of the femoral shaft was measured proximal to the level of the
fracture to eliminate improper measurement due to any post-ﬁxation mal-
alignment. When rotation of the limb precluded visualization of the neck-shaft
junction, the hip was excluded from measurement.
Statistical Analysis
An independent two-sample t test for continuous variables was used to com-
pare the results between the control and study populations and within the study
population. All statistical assessments were two-sided and were evaluated at the
0.05 level of signiﬁcance.
Source of Funding
One senior author (M.G.) received research coordinator support from Synthes.
Results
The mean neck-shaft angle in the case group (129.5) wassigniﬁcantly lower (p < 0.001) than that in the controls
(133.8). The mean neck-shaft angle on the pathologic sides(s)
in the case group (129.9) was also signiﬁcantly lower (p < 0.001)
than the mean angle in the control group.
TABLE I Patient Characteristics
Case Control
No. of patients 111 33
No. of hips available for measurement 193 62
Mean age (range) (yr) 68.7 (46-91) 66.8 (39-85)
Mean bisphosphonate exposure (range) (yr) 7.4 (1-20)* 5 (1-14)
Fracture characteristics (no. of patients)
Complete 88 —
Stress reaction/beaking 23 —
Bilateral 42 (38%) —
Bilateral complete 22 —
Complete and contralateral stress 15 —
Bilateral stress 5 —
*Not quantiﬁed for thirteen patients.
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Side-to-side comparison of patients with a unilateral
pathologic involvement did not demonstrate any signiﬁcant dif-
ference in the neck-shaft angle between the pathologic side
(129.8) and the asymptomatic, contralateral lower limb (128.2).
The lowest recorded neck-shaft angle was 128 in the
control group and118 in the case group. Fifty-three (48%) of
the patients in the case group had a neck-shaft angle of <128
on the pathologic side (Fig. 1).
Discussion
Atypical femoral fractures represent a challenge for patientswith osteoporosis and osteopenia. Many have speculated
about the etiology, and it is likely multifactorial, although no
underlying mechanism has been demonstrated. This study was
designed to determine if patients with atypical fractures have a
more varus proximal femoral geometry than an age and exposure-
matched control group. The mean neck-shaft angle of the patients
with a fracturewas signiﬁcantly lower than that of the controls, and
no control patient had a neck-shaft angle <128. Overall, we
found an association between proximal femoral geometry and
the presence of atypical femoral fractures in this population.
In the recently updated ASBMR task force consensus
statement, it was concluded that atypical femoral fractures may
represent stress fractures that progress over time7. These stress
fractures are unique in that the transverse component of the
fracture begins in the lateral cortex, whereas exercise-induced
stress fractures typically initiate in the medial cortex. Very little
is known about femoral geometry in this patient population.
Proximal femoral strength is decreased with a varus mechanical
axis10,11. Biomechanical studies have shown that trochanteric
and femoral shaft fractures are more common in patients with
low neck-shaft angles12,13. Koh et al. reviewed the radiographs of
forty-eight patients with atypical fractures and found that the
fractures clustered in the lateral cortex at the region of maximal
tensile loading14. Sasaski et al. measured the variations in the
anatomic axes of the femora of patients with “low-energy”
femoral shaft fractures15. These patients were taking medi-
cations for osteoporosis but not speciﬁcally bisphosphonates.
The patients with fractures had a signiﬁcant increase in the
lateral and anterior bow of the femur, and this geometry was
thought to result in an imbalance in strains seen in the femur.
We believe that this imbalance also occurs with an alteration
in the mechanical axis of the lower extremity produced by a
varus femoral neck.
A large number of patients in our case group had a neck-
shaft angle of <128 on the pathologic side. The study was not
powered to calculate the sensitivity and speciﬁcity of a neck-
shaft angle of <128 predicting the risk of fracture, but
studying this risk in a larger cohort would be useful.
A large proportion (38%) of the patients in our study had
bilateral pathological involvement. This is consistent with the
ﬁndings from the study performed by Lo and colleagues, in
which 40% of the population had bilateral complete fracture,
and an additional 21% had contralateral stress-reaction changes16.
They found a higher proportion of fractures in women of Asian
descent, a factor not controlled for in our study. Nakamura
et al. found that women of Japanese descent had lower neck-
shaft angles than white American women, and Japanese-
descent women could be an at-risk subset of the population17.
This stresses the importance of obtaining imaging of both
femora in patients with a history of atypical femoral fracture
and thigh pain.
Fig. 1
Plot of neck-shaft angles (NSA) in each group.
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Our study is limited by all of the factors that routinely
affect retrospective reviews. We did not control for patient fac-
tors, including body mass index, smoking status, activity level,
and bone mineral density. Also, we studied only a small sample
of the more than 4 million women on bisphosphonate therapy
in the United States.
The reliability of hip measurements has been studied
with a variety of modalities in patients with various patho-
logical conditions. In general, the reliability of the neck-shaft
angle has been shown to be good. A recent study of patients
with cerebral palsy showed an overall intraobserver and in-
terobserver reliability of neck-shaft-angle measurements on
hip radiographs of 0.929 and 0.912, respectively18. Marmor
et al. found that neck-shaft-angle measurements varied <5
with <35 of limb rotation, and the measurements were
always greater than the true value19. Thus, it is unlikely that our
measurements overestimated the actual varus in our patients; if
anything, they underestimated it. Many of the measurements in
the group with a complete fracture were performed on injury
radiographs, for which rotation is themost difﬁcult to control, and
it is likely the true neck-shaft angle in this group was in even more
varus than we reported.
Bias could have been introduced into the measurements as
the majority of those in the case group were done on injury
radiographs or radiographs showing the stress reaction; therefore,
the reviewers were not blinded to the presence of the pathological
condition. It was impossible to avoid this as many of the patients
had not sought treatment at our facilities prior to their injury or
did not have any reason to have pelvic radiographs prior to the
development of symptoms. However, there was not a signiﬁcant
difference between the measurements on the pathologic and non-
pathologic sides of our study group, thus providing a marker for
internal validity of our measurement techniques.
Another limitation of this study is that the average bis-
phosphonate exposure times of the study and control patients
were not identical. Thirteen patients in the case group did
not have numerical documentation of their duration of bis-
phosphonate use; charts indicated it was “long term.” Despite
this, the mean exposure times for both groups were greater than
those previously documented to incur risk4,8. The link between
atypical femoral fracture and bisphosphonates is an association; it
has not been deﬁnitively shown to be causation. The exact du-
ration of exposure that is needed for an increased fracture risk is
unknown. Schilcher et al. found the odds ratio of fracture to be
ten times higher after just two years of exposure8. As our study
was a retrospective analysis and we documented fracture or stress
reaction in all of the patients in the case group, we can assume
that it was an at-risk population. It is possible that the control
group was evaluated early in the time course of their disease. We
have no current method for monitoring their progression to
fracture. A prospective and longitudinal study could better con-
trol for this factor by documenting the duration of patients’ ex-
posure to bisphosphonates at the time of enrollment and more
thoroughly tracking their actual use. The ability to monitor for
progression to fracture would help determine the relative risk of
fracture.
In conclusion, we found an association between varus
proximal femoral geometry and a propensity to sustain atypical
femoral fractures in patients on long-term bisphosphonate
therapy. We agree with the ASBMR task force’s conclusion that
more needs to be done to evaluate the impact of femoral ge-
ometry on this patient population16. The neck-shaft angle is
only one variable, but it appears to have a high correlation with
atypical femoral fractures, and follow-up measurements are
easy, low cost, and noninvasive. The strength of this study was
insufﬁcient for us to conclusively advise a change in manage-
ment of these patients at this time, but we have made a strong
argument to use this as a pilot study to prompt further inves-
tigation. At a minimum, patients should be counseled to be
aware of symptoms that accompany these injuries. Larger studies
should be done in a longitudinal fashion to determine the true
risk of progression to fracture. While this is likely only one piece of
the picture, we think that our ﬁndings add a useful clinical marker
that could help identify an at-risk subset of this population. n
NOTE: The authors acknowledge Justin Langan for his contribution to the data-collection portion of
this project.
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